ArticleBiomaterials2013
The use of surface immobilization of P-selectin glycoprotein ligand-1 on mesenchymal stem cells to facilitate selectin mediated cell tethering and rolling.
Article in Biomaterials, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 52 citations in OpenAlex.
- Bioengineered Mesenchymal Stem/Stromal Cells in Anti-Cancer Therapy: Current Trends and Future Prospects.Biomolecules · 2024Review
- Let's Get Rolling: Precise Control of Microfluidic Assay Conditions to Recapitulate Selectin-Mediated Rolling Interactions of the Leukocyte Adhesion Cascade.Current protocols · 2024Article
- Efficient delivery of mesenchymal stem/stromal cells to injured liver by surface PEGylation.Stem cell research & therapy · 2023Article
- Research progress of engineered mesenchymal stem cells and their derived exosomes and their application in autoimmune/inflammatory diseases.Stem cell research & therapy · 2023Review
- Editing a gateway for cell therapy across the blood-brain barrier.Brain : a journal of neurology · 2023Review
- Cell-specific targeting of extracellular vesicles through engineering the glycocalyx.Journal of extracellular vesicles · 2022Article
- Manipulating Cell Fates with Protein Conjugates.Bioconjugate chemistry · 2022Review
- Modified mesenchymal stem cells in cancer therapy: A smart weapon requiring upgrades for wider clinical applications.World journal of stem cells · 2022Review
- Neutrophils aid cellular therapeutics by enhancing glycoengineered stem cell recruitment and retention at sites of inflammation.Biomaterials · 2021Article
- Cell augmentation strategies for cardiac stem cell therapies.Stem cells translational medicine · 2021Review
- Mesenchymal Stem Cells for Neurological Disorders.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2021Review
- Stem Cell Mimicking Nanoencapsulation for Targeting Arthritis.International journal of nanomedicine · 2021Review
- The Current Status of Mesenchymal Stromal Cells: Controversies, Unresolved Issues and Some Promising Solutions to Improve Their Therapeutic Efficacy.Frontiers in cell and developmental biology · 2021Review
- Multi-modal imaging probe for assessing the efficiency of stem cell delivery to orthotopic breast tumours.Nanoscale · 2020Article
- Shattering barriers toward clinically meaningful MSC therapies.Science advances · 2020Review
- Targeted Repair of Vascular Injury by Adipose-Derived Stem Cells Modified with P-Selectin Binding Peptide.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2020Article
- Don't sugarcoat it: How glycocalyx composition influences cancer progression.The Journal of cell biology · 2020Review
- Review
- Selectins and Immune Cells in Acute Myocardial Infarction and Post-infarction Ventricular Remodeling: Pathophysiology and Novel Treatments.Frontiers in immunology · 2019Review
- Programming Cell-Cell Interactions through Non-genetic Membrane Engineering.Cell chemical biology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
Abstract
Mesenchymal stem/stromal cells (MSCs) are an important candidate for cell-based therapy since they can be easily isolated and expanded, secrete beneficial paracrine factors, and differentiate into multiple lineages. Since the endothelium at sites of injury and inflammation often express adhesion molecules belonging to the selectin family, methods to endow MSCs with selectin-ligands can enhance the efficacy of cell delivery and tissue engraftment. Here, we describe a construct 19Fc[FUT7(+)], where the first 19 amino acids of the pan-selectin ligand PSGL-1 (P-selectin glycoprotein ligand-1) was fused to a human IgG1. When expressed in HEK293T cells over-expressing the α(1,3)fucosyltransferase FUT7, 19Fc[FUT7(+)] is decorated by a core-2 sialyl Lewis-X sialofucosylated O-glycan. The non-covalent coupling of this protein onto MSC surface using palmitated protein G (PPG) enhanced cell binding to E- and P-selectin under hydrodynamic shear, without altering MSC multipotency. MSCs functionalized with 19Fc[FUT7(+)] were captured/tethered onto stimulated endothelial cell monolayers at wall shear stresses up to 4 dyn/cm(2). Once captured, the cells rolled robustly up to the highest shear stress tested, 10 dyn/cm(2). Unlike previous work where MSCs could only be captured onto selectin-bearing substrates at low or no-flow conditions, the current work presents a 'glycan engineering' strategy to enable leukocyte-like capture and rolling.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.